SCHEMBL4872129

SCHEMBL4872129

COc1ccc(S(=O)(=O)NCC(=O)Nc2ccc(Cl)cc2C(O)c2cccc(Cl)c2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
KMT2A Q03164 1/20 0.47
F2 P00734 2/20 0.46
ALDH1A1 P00352 5/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
PKM P14618 1/20 0.46
CYP2C19 P33261 1/20 0.46
TMPRSS6 Q8IU80 1/20 0.46
TP53 P04637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
MAPK1 P28482 2/20 0.42
MEP1B Q16820 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3244779 0.94 MEP1B (0.46) TSHRKMT2AF2ALDH1A1CYP1A2
SCHEMBL3247678 0.94 TSHR (0.53) TSHRKMT2AF2ALDH1A1TMPRSS6
SCHEMBL3252883 0.90 TSHR (0.48) TSHRKMT2AF2ALDH1A1CYP1A2
SCHEMBL3256167 0.89 MAPK1 (0.47) TSHRKMT2AF2ALDH1A1TMPRSS6
SCHEMBL3252098 0.89 TSHR (0.49) TSHRKMT2AF2ALDH1A1TMPRSS6
SCHEMBL3244635 0.89 MEP1B (0.46) TSHRKMT2AF2ALDH1A1TMPRSS6
SCHEMBL3246588 0.89 MEP1B (0.48) TSHRKMT2AF2ALDH1A1CYP1A2
SCHEMBL4869386 0.89 TSHR (0.47) TSHRKMT2AF2ALDH1A1CYP1A2
SCHEMBL3256172 0.89 HTT (0.48) TSHRKMT2AF2ALDH1A1TMPRSS6
SCHEMBL3251279 0.88 KMT2A (0.48) TSHRKMT2AF2ALDH1A1TMPRSS6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 TSHR 29/4885KMT2A 1181/4885F2 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.